Cargando…

How Durable Is Functional Cure (Hepatitis B Surface Antigen Loss) in Patients With Chronic Hepatitis B Treated With Current Antivirals?

Detalles Bibliográficos
Autores principales:	Loglio, Alessandro, Lampertico, Pietro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6939499/ https://www.ncbi.nlm.nih.gov/pubmed/31909351 http://dx.doi.org/10.1002/hep4.1476

Ejemplares similares

Towards a Functional Cure for Hepatitis B Virus: A 2022 Update on New Antiviral Strategies
por: Degasperi, Elisabetta, et al.
Publicado: (2022)

Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis B
por: Lok, Anna S., et al.
Publicado: (2019)

Quantitative Hepatitis B Surface Antigen, the Trustworthy Biomarker for Functional Cure of Chronic Hepatitis B
por: Choi, Jonggi
Publicado: (2023)

Hepatitis Delta Virus Acts as an Immunogenic Adjuvant in Hepatitis B Virus-Infected Hepatocytes
por: Tham, Christine Y.L., et al.
Publicado: (2020)

Functional cure for chronic hepatitis B: accessibility, durability, and prognosis
por: Song, Aixin, et al.
Publicado: (2021)

Soluble programmed death-1 is predictive of hepatitis B surface antigen loss in chronic hepatitis B patients after antiviral treatment
por: Tan, Ning, et al.
Publicado: (2021)

The Impact of Antiviral Treatment of Hepatitis B Virus after Kidney Transplant and the Latest Insights
por: Fabrizi, Fabrizio, et al.
Publicado: (2023)

Quantitative hepatitis B surface antigen predicts the antiviral response and hepatocellular carcinoma development in patients with chronic hepatitis B
por: Kim, Sung Eun
Publicado: (2017)

Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B
por: Lee, Han Ah, et al.
Publicado: (2016)

Current Antiviral Therapy for Chronic Hepatitis B
por: Lim, Young-Suk, et al.
Publicado: (2004)

Clinical Implications of HBsAg Quantification in Patients with Chronic Hepatitis B
por: Viganò, Mauro, et al.
Publicado: (2012)

Hepatitis B Surface Antigen Loss and Hepatocellular Carcinoma Development in Patients With Dual Hepatitis B and C Infection
por: Yang, Wan-Ting, et al.
Publicado: (2016)

Kinetics of Hepatitis B Surface Antigen Level in Chronic Hepatitis B Patients who Achieved Hepatitis B Surface Antigen Loss during Pegylated Interferon Alpha-2a Treatment
por: Li, Ming-Hui, et al.
Publicado: (2017)

Durability of hepatitis B surface antigen seroclearance and subsequent risk for hepatocellular carcinoma: A meta‐analysis
por: Song, Aixin, et al.
Publicado: (2021)

Clinical features of chronic hepatitis B patients with low hepatitis B surface antigen levels and determinants of hepatitis B surface antigen seroclearance
por: Taniguchi, Hideaki, et al.
Publicado: (2020)

Off-treatment durability of antiviral response to nucleoside analogues in patients with chronic hepatitis B
por: Nagata, Naruhiko, et al.
Publicado: (2016)

Seroconversion of Hepatitis B Virus Surface Antigen in Chronic Hepatitis B Child Treated with Entecavir
por: Li, Dong, et al.
Publicado: (2012)

Overlapping Gene Mutations of Hepatitis B Virus in a Chronic Hepatitis B Patient with Hepatitis B Surface Antigen Loss during Lamivudine Therapy
por: Lee, Sun-Young, et al.
Publicado: (2005)

Clinical Utility of SCALE-B to Predict Hepatitis B Virus Relapse, Hepatitis B Surface Antigen Loss After Antiviral Cessation in Asian Patients After 2-Year Follow-up
por: Kaewdech, Apichat, et al.
Publicado: (2022)

How to compare antivirals in the treatment of chronic hepatitis B?
por: Ozaras, Resat, et al.
Publicado: (2009)

Correlation Between Quantitative Hepatitis B Surface Antigen and Hepatitis B Virus Deoxyribonucleic Acid Levels in Hepatitis B e Antigen-Positive and Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients
por: Nirmala, Viva Finhar Insani, et al.
Publicado: (2023)

Current Trend in Antiviral Therapy for Chronic Hepatitis B
por: Chien, Rong-Nan, et al.
Publicado: (2022)

High Hepatitis B Surface Antigen Levels Predict Insignificant Fibrosis in Hepatitis B e Antigen Positive Chronic Hepatitis B
por: Seto, Wai-Kay, et al.
Publicado: (2012)

Association of Cytokines with Alanine Aminotransferase, Hepatitis B Virus Surface Antigen and Hepatitis B Envelope Antigen Levels in Chronic Hepatitis B
por: Li, Ming-Hui, et al.
Publicado: (2018)

Expression of Hepatocyte Hepatitis B Core Antigen and Hepatitis B Surface Antigen as a Marker in the Management of Chronic Hepatitis B Patients
por: Yim, Sun Young, et al.
Publicado: (2017)

Cellular immune responses in patients with hepatitis B surface antigen seroclearance induced by antiviral therapy
por: Liang, Minfeng, et al.
Publicado: (2011)

Integrated hepatitis B virus DNA maintains surface antigen production during antiviral treatment
por: Grudda, Tanner, et al.
Publicado: (2022)

Cytokines and Chemokines Involved in Hepatitis B Surface Antigen Loss in Human Immunodeficiency Virus/Hepatitis B Virus Coinfected Patients
por: Urata, Noboru, et al.
Publicado: (2021)

Thyroid dysfunction is associated with the loss of hepatitis B surface antigen in patients with chronic hepatitis B undergoing treatment with α-interferon
por: Luo, Wenfan, et al.
Publicado: (2021)

Serum hepatitis B surface antigen (HBsAg) kinetics in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B
por: Seto, Wai-Kay, et al.
Publicado: (2012)

Maternal hepatitis B e antigen can be an indicator for antiviral prophylaxis of perinatal transmission of hepatitis B virus
por: Lu, Ying, et al.
Publicado: (2021)

Detecting Hepatitis B Surface Antigen Mutants
por: Coleman, Paul F.
Publicado: (2006)

Hepatitis B Surface Antigen Could Contribute to the Immunopathogenesis of Hepatitis B Virus Infection
por: Kondo, Yasuteru, et al.
Publicado: (2013)

Reactivation of hepatitis B virus with mutated hepatitis B surface antigen in a liver transplant recipient receiving a graft from an antibody to hepatitis B surface antigen– and antibody to hepatitis B core antigen–positive donor
por: Blaich, Annette, et al.
Publicado: (2012)

Risk of Reactivation of Hepatitis B in Hepatitis B Surface Antigen-Negative and Hepatitis B Core Antigen Antibody Positive Patients Receiving Biologic Therapy
por: Gök Sargın, Zeynep
Publicado: (2023)

Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety
por: Lam, Yuk-Fai, et al.
Publicado: (2011)

A genotype-specific baseline score predicts post-treatment response to peginterferon alfa-2a in hepatitis B e antigen-negative chronic hepatitis B
por: Lampertico, Pietro, et al.
Publicado: (2018)

Effects of hepatitis B vaccination on hepatitis B surface antigen in neonates and its change in vivo
por: Wang, Shuqi, et al.
Publicado: (2023)

What will it take to cure hepatitis B?
por: Jeng, Wen-Juei, et al.
Publicado: (2023)

The clinical value of serum hepatic parenchyma cell volume-normalized hepatitis B surface antigen levels in hepatitis B e antigen -positive and -negative chronic hepatitis B patients
por: Tan, Lei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fse6po721v1kg4i4i269gvijr5